JP2016526014A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016526014A5 JP2016526014A5 JP2016510767A JP2016510767A JP2016526014A5 JP 2016526014 A5 JP2016526014 A5 JP 2016526014A5 JP 2016510767 A JP2016510767 A JP 2016510767A JP 2016510767 A JP2016510767 A JP 2016510767A JP 2016526014 A5 JP2016526014 A5 JP 2016526014A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- amino acid
- antibody
- substitution
- helix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 114
- 238000006467 substitution reaction Methods 0.000 claims 38
- 125000000539 amino acid group Chemical group 0.000 claims 32
- 239000008194 pharmaceutical composition Substances 0.000 claims 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims 23
- 108091005601 modified peptides Proteins 0.000 claims 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 19
- 208000035475 disorder Diseases 0.000 claims 11
- 230000004048 modification Effects 0.000 claims 10
- 238000012986 modification Methods 0.000 claims 10
- 229920001223 polyethylene glycol Polymers 0.000 claims 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 238000012216 screening Methods 0.000 claims 6
- 230000004071 biological effect Effects 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 239000000178 monomer Substances 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 230000000704 physical effect Effects 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 102000003814 Interleukin-10 Human genes 0.000 claims 4
- 108090000174 Interleukin-10 Proteins 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 238000007792 addition Methods 0.000 claims 4
- 238000003556 assay Methods 0.000 claims 4
- 238000012217 deletion Methods 0.000 claims 4
- 230000037430 deletion Effects 0.000 claims 4
- 230000005847 immunogenicity Effects 0.000 claims 4
- 238000000099 in vitro assay Methods 0.000 claims 4
- 238000002347 injection Methods 0.000 claims 4
- 239000007924 injection Substances 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 230000000069 prophylactic effect Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 230000002411 adverse Effects 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 230000003993 interaction Effects 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 230000001954 sterilising effect Effects 0.000 claims 3
- 238000004659 sterilization and disinfection Methods 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 102000009027 Albumins Human genes 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 101001033233 Homo sapiens Interleukin-10 Proteins 0.000 claims 2
- 102000007562 Serum Albumin Human genes 0.000 claims 2
- 108010071390 Serum Albumin Proteins 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000001516 cell proliferation assay Methods 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 102000052620 human IL10 Human genes 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 238000000126 in silico method Methods 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000005462 in vivo assay Methods 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000019838 Blood disease Diseases 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 206010014476 Elevated cholesterol Diseases 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 230000000975 bioactive effect Effects 0.000 claims 1
- 150000001720 carbohydrates Chemical group 0.000 claims 1
- 150000004665 fatty acids Chemical group 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 150000004676 glycans Polymers 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 150000002632 lipids Chemical group 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 150000004804 polysaccharides Polymers 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361815657P | 2013-04-24 | 2013-04-24 | |
| US61/815,657 | 2013-04-24 | ||
| PCT/US2014/035201 WO2014176373A2 (en) | 2013-04-24 | 2014-04-23 | Interleukin-10 compositions and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016526014A JP2016526014A (ja) | 2016-09-01 |
| JP2016526014A5 true JP2016526014A5 (enExample) | 2017-06-01 |
Family
ID=51792509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016510767A Pending JP2016526014A (ja) | 2013-04-24 | 2014-04-23 | インターロイキン−１０組成物及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20160068583A1 (enExample) |
| EP (1) | EP2989240A4 (enExample) |
| JP (1) | JP2016526014A (enExample) |
| AU (1) | AU2014257123A1 (enExample) |
| CA (1) | CA2908208A1 (enExample) |
| HK (1) | HK1215595A1 (enExample) |
| WO (1) | WO2014176373A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
| WO2012036746A1 (en) | 2010-09-15 | 2012-03-22 | Randall J Mrsny | Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences |
| JP2016528879A (ja) | 2013-06-17 | 2016-09-23 | アルモ・バイオサイエンシーズ・インコーポレイテッド | タンパク質の同一性および安定性を評価する方法 |
| HK1226308A1 (zh) * | 2013-08-30 | 2017-09-29 | Armo Biosciences, Inc. | 使用白细胞介素-10治疗疾病和病症的方法 |
| US11413332B2 (en) | 2013-11-11 | 2022-08-16 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| SG11201610183XA (en) | 2014-05-07 | 2017-01-27 | Applied Molecular Transp Llc | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
| US10293043B2 (en) | 2014-06-02 | 2019-05-21 | Armo Biosciences, Inc. | Methods of lowering serum cholesterol |
| JP6675394B2 (ja) | 2014-10-22 | 2020-04-01 | アルモ・バイオサイエンシーズ・インコーポレイテッド | 疾患及び障害の治療のためにインターロイキン−１０を使用する方法 |
| WO2016100788A1 (en) | 2014-12-19 | 2016-06-23 | Alkermes, Inc. | Single chain fc fusion proteins |
| US10618970B2 (en) | 2015-02-03 | 2020-04-14 | Armo Biosciences, Inc. | Method of treating cancer with IL-10 and antibodies that induce ADCC |
| US20160361415A1 (en) | 2015-05-28 | 2016-12-15 | Armo Biosciences, Inc. | Methods of Using Interleukin-10 for Treating Diseases and Disorders |
| JP7053453B2 (ja) | 2015-08-25 | 2022-04-12 | アルモ・バイオサイエンシーズ・インコーポレイテッド | 疾患及び障害を治療するためのインターロイキン１０の使用方法 |
| WO2017087768A1 (en) | 2015-11-18 | 2017-05-26 | Duke University | Targeted delivery of interleukin-10 to tumor infiltrating lymphocytes |
| CA3026393C (en) | 2016-06-22 | 2023-03-14 | Alkermes, Inc. | Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| ES2949940T3 (es) * | 2017-03-14 | 2023-10-04 | Sjt Molecular Res Sl | Compuestos para uso en la prevención y/o el tratamiento de esteatosis hepática no alcohólica y esteatohepatitis no alcohólica |
| US20200353050A1 (en) | 2017-11-10 | 2020-11-12 | Armo Biosciences, Inc. | Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors |
| EP3810189A1 (en) | 2018-06-19 | 2021-04-28 | Armo Biosciences, Inc. | Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy |
| JP7487193B2 (ja) | 2018-11-07 | 2024-05-20 | アプライド モレキュラー トランスポート インコーポレイテッド | 異種ペイロードの経口送達のためのコリックス由来担体 |
| TW202033766A (zh) * | 2018-11-26 | 2020-09-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種人白細胞介素１０變體及其衍生物 |
| WO2020172631A2 (en) | 2019-02-21 | 2020-08-27 | Xencor, Inc. | Untargeted and targeted il-10 fc-fusion proteins |
| CN121971599A (zh) | 2019-02-25 | 2026-05-05 | 芝加哥大学 | 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物 |
| BR102019007048A8 (pt) * | 2019-04-05 | 2023-05-09 | Univ Federal De Uberlandia | Combinação de peptídeos sintéticos com afinidade ao receptor de tgf-beta e com afinidade ao receptor de il-10, composição farmacêutica e uso dos mesmos como imunomuduladores no tratamento de doenças autoimunes, inflamatórias ou alérgicas |
| CN114599665A (zh) | 2019-08-16 | 2022-06-07 | 应用分子转运公司 | 组合物、制剂及白细胞介素产生和纯化 |
| AU2020394444B2 (en) | 2019-11-25 | 2025-05-29 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| GB202003428D0 (en) * | 2020-03-10 | 2020-04-22 | Univ Dundee | IL-10 mutiens |
| CR20230025A (es) * | 2020-06-26 | 2023-10-05 | Amgen Inc | Muteínas de il-10 y proteínas de fusión de las mismas referencia cruzada a solicitudes relacionadas |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| CA3239849A1 (en) * | 2021-12-01 | 2023-06-08 | Michael Wong | Il10 variants and uses thereof |
| CN118240058A (zh) * | 2022-12-24 | 2024-06-25 | 广东菲鹏制药股份有限公司 | Il10突变体、融合蛋白和药物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL110413A0 (en) * | 1993-07-26 | 1994-10-21 | Schering Corp | Agonists and antagonists of human interleukin-10 |
| CN1269805A (zh) * | 1997-07-14 | 2000-10-11 | 博尔德生物技术公司 | 生长激素和相关蛋白的衍生物 |
| US6428985B1 (en) * | 1998-12-02 | 2002-08-06 | The Regents Of The University Of Michigan | Immunosuppressive structural definition of IL-10 |
| US20030186386A1 (en) * | 2000-02-11 | 2003-10-02 | Hansen Christian Karsten | Interleukin 10 |
| EP1257574A1 (en) * | 2000-02-11 | 2002-11-20 | Maxygen Aps | Improved interleukin 10 |
| IL152804A0 (en) * | 2000-05-16 | 2003-06-24 | Bolder Biotechnology Inc | Methods for refolding proteins containing free cysteine residues |
| ATE516820T1 (de) * | 2000-09-29 | 2011-08-15 | Schering Corp | Pegyliertes interleukin 10 |
| CA2498319A1 (en) * | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
| AU2003280315A1 (en) * | 2002-11-14 | 2004-06-03 | Maxygen, Inc. | Conjugates of interleukin-10 and polymers |
| AU2003303222A1 (en) * | 2002-12-19 | 2004-07-14 | Universiteit Gent | Mutant proteins showing increased secretion |
| AU2003303636B2 (en) * | 2002-12-26 | 2010-08-05 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
| US7749490B2 (en) * | 2005-05-31 | 2010-07-06 | The Regents Of The University Of Colorado | Mutant IL-10 |
| WO2007003041A1 (en) * | 2005-07-01 | 2007-01-11 | John Schrader | Methods of isolating cells and generating monoclonal antibodies |
| US7868139B2 (en) * | 2006-01-24 | 2011-01-11 | Uab Research Foundation | Compositions and methods for the identification and treatment of immune-mediated inflammatory diseases |
| CA2706700A1 (en) * | 2007-11-08 | 2009-05-14 | Cytimmune Sciences, Inc. | Compositions and methods for generating antibodies |
| CN102711829B (zh) * | 2009-11-30 | 2016-03-16 | 生物测试股份公司 | 治疗系统性红斑狼疮(sle)的人源化抗il-10抗体 |
| WO2013130913A1 (en) * | 2012-02-29 | 2013-09-06 | Ambrx, Inc. | Interleukin-10 polypeptide conjugates and their uses |
-
2014
- 2014-04-23 CA CA2908208A patent/CA2908208A1/en not_active Abandoned
- 2014-04-23 JP JP2016510767A patent/JP2016526014A/ja active Pending
- 2014-04-23 EP EP14788854.9A patent/EP2989240A4/en not_active Withdrawn
- 2014-04-23 WO PCT/US2014/035201 patent/WO2014176373A2/en not_active Ceased
- 2014-04-23 HK HK16102717.0A patent/HK1215595A1/zh unknown
- 2014-04-23 US US14/779,928 patent/US20160068583A1/en not_active Abandoned
- 2014-04-23 AU AU2014257123A patent/AU2014257123A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113573782B (zh) | 针对人pd-1的双功能分子 | |
| JP6448368B2 (ja) | 免疫グロブリンＦｃ変異体 | |
| EP2274331B1 (en) | Improved fibronectin-based binding molecules and uses thereof | |
| JP2021072847A (ja) | Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質 | |
| CN102665759B (zh) | 人源化抗il-22ra抗体 | |
| JP2017524713A (ja) | Ｉｌ−２およびインテグリン結合性ｆｃ融合タンパク質による相乗的な腫瘍処置 | |
| JP2019503348A5 (enExample) | ||
| CN102625811B (zh) | Fgf21突变体及其用途 | |
| JP2018528234A (ja) | 免疫グロブリン断片の特定位置を連結部位として用いたタンパク質結合体 | |
| JP2015507628A5 (enExample) | ||
| AU2017205270A1 (en) | Therapeutic anticancer neoepitope vaccine | |
| EP3161007A1 (en) | Multispecific antibody constructs | |
| JP2012527875A5 (enExample) | ||
| JP2023103368A5 (enExample) | ||
| EP3568417A1 (en) | Anti-pd-l1 antibody and il-7 fusions | |
| CA3127144A1 (en) | Cd3-specific binding molecules | |
| AU2020338947A1 (en) | Modified TFF2 polypeptides | |
| WO2017059371A1 (en) | Treatment of bile acid disorders | |
| EP1545609B1 (en) | Antibodies directed against oxidised apolipoprotein B | |
| CN109929037B (zh) | 针对程序性死亡配体的结合物及其应用 | |
| CN110272495A (zh) | 一种能结合两种抗原的双特异性结合的免疫球蛋白及其用途 | |
| EP4168432A1 (en) | Cxcl9 and variants thereof for immunotherapy of cancer diseases | |
| CN114829385A (zh) | 包含il-7变体的双功能分子 | |
| WO2020193745A1 (en) | Binding molecules specfic for hbv envelope protein | |
| WO2021260685A1 (en) | Modified cxcl10 for immunotherapy of cancer diseases |